Alkermes plc. Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31)
Alkermes plc. (ALKS) reported Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31) of $101.00 million for the 9-month period ending 2013-12-31, per its 10-KT filed 2014-02-27.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount · last filed 2014-02-27
- Alkermes plc. stock repurchase program, remaining authorized repurchase amount (deprecated 2014-01-31) for fiscal 2013 was $101.00M, a 0.00% change from fiscal 2012.
- Alkermes plc. stock repurchase program, remaining authorized repurchase amount (deprecated 2014-01-31) for fiscal 2012 was $101.00M.
| Period end | Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31) 9 month | Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31) 12 month |
|---|---|---|
| 2013-12-31 | $101.00M 10-KT · filed 2014-02-27 | |
| 2013-03-31 | $101.00M 10-K · filed 2013-05-23 | |
| 2012-03-31 | $101.00M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |